Iterum Therapeutics Company Leadership
| ITRM Stock | USD 1.57 0.07 4.67% |
About 64% of Iterum Therapeutics' corporate insiders are selling. The analysis of insiders' sentiment of trading Iterum Therapeutics PLC stock suggests that many insiders are alarmed at this time. Iterum Therapeutics employs about 14 people. The company is managed by 7 executives with a total tenure of roughly 33 years, averaging almost 4.0 years of service per executive, having 2.0 employees per reported executive.
| Corey Fishman CEO CEO, Director |
Iterum Therapeutics' Insider Buying Vs Selling
36
Selling | Buying |
Latest Trades
| 2023-12-22 | Michael W Dunne | Acquired 25000 @ 1.4 | View | ||
| 2023-11-22 | Michael W Dunne | Acquired 20000 @ 2.03 | View | ||
| 2023-11-20 | Corey N Fishman | Acquired 10000 @ 1.59 | View | ||
| 2022-12-02 | Sailaja Puttagunta | Disposed 3365 @ 1.32 | View | ||
| 2022-09-19 | Brenton Karl Ahrens | Disposed 15000 @ 1.77 | View | ||
| 2022-09-16 | Brenton Karl Ahrens | Disposed 15000 @ 1.9 | View | ||
| 2022-09-14 | Brenton Karl Ahrens | Disposed 15000 @ 2.1 | View | ||
| 2022-09-12 | Brenton Karl Ahrens | Disposed 15000 @ 2.31 | View | ||
| 2022-09-09 | Brenton Karl Ahrens | Disposed 15000 @ 2.32 | View | ||
| 2022-09-07 | Michael W Dunne | Acquired 10000 @ 2.22 | View | ||
| 2022-03-14 | Judith M Matthews | Disposed 47132 @ 0.38 | View |
Monitoring Iterum Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Iterum |
Iterum Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7335) % which means that it has lost $0.7335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5568) %, meaning that it created substantial loss on money invested by shareholders. Iterum Therapeutics' management efficiency ratios could be used to measure how well Iterum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Equity is likely to grow to 5.66, while Return On Tangible Assets are likely to drop (1.76). At this time, Iterum Therapeutics' Total Assets are very stable compared to the past year. As of the 31st of January 2025, Total Current Assets is likely to grow to about 47 M, while Non Current Assets Total are likely to drop about 724.3 K.As of the 31st of January 2025, Common Stock Shares Outstanding is likely to drop to about 14.2 M. In addition to that, Net Loss is likely to drop to about (42 M)
Iterum Therapeutics Workforce Comparison
Iterum Therapeutics PLC is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 717. Iterum Therapeutics claims roughly 14.0 in number of employees contributing just under 2% to equities under Health Care industry.
Iterum Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iterum Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iterum Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Iterum Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iterum Therapeutics Notable Stakeholders
An Iterum Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Iterum Therapeutics often face trade-offs trying to please all of them. Iterum Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Iterum Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Corey Fishman | CEO, Director | Profile | |
| Sailaja MD | Chief Officer | Profile | |
| Tom Loughman | Senior Operations | Profile | |
| Steven MD | Senior Development | Profile | |
| Louise Barrett | Senior Secretary | Profile | |
| Michael MD | Strategic Director | Profile | |
| Judith Matthews | Chief Officer | Profile |
About Iterum Therapeutics Management Performance
The success or failure of an entity such as Iterum Therapeutics PLC often depends on how effective the management is. Iterum Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Iterum management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Iterum management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.68) | (1.76) | |
| Return On Capital Employed | (4.28) | (4.07) | |
| Return On Assets | (1.68) | (1.76) | |
| Return On Equity | 5.39 | 5.66 |
Iterum Therapeutics Workforce Analysis
Traditionally, organizations such as Iterum Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Iterum Therapeutics within its industry.Iterum Therapeutics Manpower Efficiency
Return on Iterum Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.7M | |
| Net Loss Per Executive | 5.5M | |
| Working Capital Per Employee | 862.7K | |
| Working Capital Per Executive | 1.7M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.